Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin

Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin

Background The suppression of chimeric antigen receptor (CAR) T cells by the tumor microenvironment (TME) is a crucial obstacle in the T-cell-based treatment of solid tumors. Extra domain B (EDB)-fibronectin is an oncofetal antigen expressed on the endothelium layer of the neovasculature and cancer...

Full description

Bibliographic Details
Main Authors: Chang Liu, Zhen Hua, Mengting Wu, Wen Qiu, Hang Wang, Zhe Yang, Zhijie Zhang, Muhan Wang, Rongcheng Sun, Yushuang Wu, Hongping Yin, Meijia Yang
Format: Article
Language:English
Published: BMJ Publishing Group 2023-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/8/e007199.full

Internet

https://jitc.bmj.com/content/11/8/e007199.full

Similar Items